 |
1 Product |  |
2 Diseases | | 1 Product |
|
1 Trial |  |
32 News |  |
- || MEDI6469 / AstraZeneca
Trial completion, Metastases: Anti-OX40 Antibody in Head and Neck Cancer Patients (clinicaltrials.gov) - Feb 7, 2024
P1, N=17, Completed, Sponsor: Providence Health & Services
Active, not recruiting --> Completed
- | MEDI6469 / AstraZeneca
Trial completion date, Metastases: Anti-OX40 Antibody in Head and Neck Cancer Patients (clinicaltrials.gov) - Dec 31, 2023
P1, N=17, Active, not recruiting, Sponsor: Providence Health & Services
- | MEDI6469 / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: Anti-OX40 Antibody in Head and Neck Cancer Patients (clinicaltrials.gov) - Jul 15, 2022
P1, N=17, Active, not recruiting, Sponsor: Providence Health & Services
Active, not recruiting --> Completed Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Apr 2022 --> Apr 2023
- ||| MEDI6469 / AstraZeneca
Trial termination, Combination therapy, IO biomarker, Metastases: Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 14, 2022
P1, N=4, Terminated, Sponsor: Providence Health & Services
PI left the institution shortly afterwards and the study will not be re-activated. Only 4 patients were enrolled.
- || Review, Journal: OX40 agonists for cancer treatment: a patent review. (Pubmed Central) - Mar 23, 2021
United States was the leader in generating patents, followed by China and England. Major pharmaceutical companies have at least one anti-OX40 agonist, MEDI6469 and MEDI-0562 (AstraZeneca), PF-04518600 (Pfizer), GSK3174998 (GlaxoSmithKline), BMS-986178 (Bristol-Myers Squibb) and MOXR0916 (Roche), which represent 68% of clinical trials conducted with OX40 agonists.
- || MEDI6469 / AstraZeneca
Clinical, Clinical Trial,Phase I, Journal, IO biomarker: Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. (Pubmed Central) - Feb 24, 2021
P1
These data provide evidence that anti-OX40 prior to surgery is safe and can increase activation and proliferation of CD4+ and CD8+ T cells in blood and tumor. Our work suggests that increases in the tumor-reactive CD103+ CD39+ CD8+ TIL could serve as a potential biomarker of anti-OX40 clinical activity.
- ||||| MEDI6469 / AstraZeneca
Clinical: Patients with HNSCC cancer were given three doses of neoadjuvant anti-OX40 (MEDI6469) at 0.4 mg/kg, followed by surgery at days 8, 12, or 19. T-cell proliferation (Ki67) & activation (ICOS) in peripheral blood following anti-OX40 administration peaks between D12 and D19. (Twitter) - Feb 16, 2021
- || MEDI6469 / AstraZeneca
Trial completion, Trial completion date, Combination therapy, Metastases: Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (clinicaltrials.gov) - Mar 6, 2019
P1/2, N=14, Completed, Sponsor: Providence Health & Services
Our work suggests that increases in the tumor-reactive CD103+ CD39+ CD8+ TIL could serve as a potential biomarker of anti-OX40 clinical activity. Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Aug 2018
- | MEDI6469 / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: Anti-OX40 Antibody in Head and Neck Cancer Patients (clinicaltrials.gov) - Nov 26, 2018
P1, N=17, Active, not recruiting, Sponsor: Providence Health & Services
Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Aug 2018 Trial completion date: Oct 2019 --> Oct 2022 | Trial primary completion date: Oct 2018 --> Apr 2022
- | cyclophosphamide / Generic mfg.
Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer (clinicaltrials.gov) - Aug 29, 2018
P1, N=13, Completed, Sponsor: Providence Health & Services
Trial completion date: Oct 2019 --> Oct 2022 | Trial primary completion date: Oct 2018 --> Apr 2022 Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | N=10 --> 13 | Trial completion date: Oct 2020 --> Jul 2016 | Trial primary completion date: Oct 2018 --> Jul 2016
- | MEDI6469 / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (clinicaltrials.gov) - Aug 16, 2018
P1/2, N=14, Active, not recruiting, Sponsor: Providence Health & Services
Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | N=10 --> 13 | Trial completion date: Oct 2020 --> Jul 2016 | Trial primary completion date: Oct 2018 --> Jul 2016 Trial completion date: Feb 2023 --> Jan 2019 | Trial primary completion date: Feb 2020 --> May 2016
- MEDI6469 / AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (clinicaltrials.gov) - Apr 4, 2018
P1/2, N=14, Active, not recruiting, Sponsor: Providence Health & Services
Trial completion date: Feb 2023 --> Jan 2019 | Trial primary completion date: Feb 2020 --> May 2016 Trial primary completion date: Feb 2018 --> Feb 2020
- MEDI6469 / AstraZeneca
Enrollment closed, Enrollment change, Combination therapy, IO biomarker, Metastases: Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2017
P1, N=4, Active, not recruiting, Sponsor: Providence Health & Services
Trial primary completion date: Feb 2018 --> Feb 2020 Recruiting --> Active, not recruiting | N=44 --> 4
- MEDI6469 / AstraZeneca
Enrollment closed, Enrollment change, IO biomarker, Metastases: Anti-OX40 Antibody in Head and Neck Cancer Patients (clinicaltrials.gov) - Aug 10, 2017
P1, N=17, Active, not recruiting, Sponsor: Providence Health & Services
Recruiting --> Active, not recruiting | N=44 --> 4 Recruiting --> Active, not recruiting | N=55 --> 17
- | MEDI6469 / AstraZeneca
Enrollment closed, Enrollment change, Combination therapy, Metastases: Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (clinicaltrials.gov) - Aug 10, 2017
P1/2, N=14, Active, not recruiting, Sponsor: Providence Health & Services
Recruiting --> Active, not recruiting | N=55 --> 17 Recruiting --> Active, not recruiting | N=40 --> 14
- MEDI6469 / AstraZeneca
Phase classification, Trial termination, Combination therapy, Metastases: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (clinicaltrials.gov) - Jun 28, 2017
P1b/2, N=48, Terminated, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | N=40 --> 14 Phase classification: P1/2 --> P1b/2 | Completed --> Terminated; The study was terminated early at the sponsor's discretion.
- cyclophosphamide / Generic mfg.
Trial primary completion date, Metastases: Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer (clinicaltrials.gov) - Jun 15, 2017
P1/2, N=10, Active, not recruiting, Sponsor: Providence Health & Services
Phase classification: P1/2 --> P1b/2 | Completed --> Terminated; The study was terminated early at the sponsor's discretion. Trial primary completion date: Oct 2016 --> Oct 2018
- |||| MEDI6469 / AstraZeneca
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (clinicaltrials.gov) - May 3, 2016
P1/2, N=58, Completed, Sponsor: MedImmune LLC
Trial primary completion date: Oct 2016 --> Oct 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016
- cyclophosphamide / Generic mfg.
Enrollment closed, Enrollment change, Metastases: Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer (clinicaltrials.gov) - Mar 29, 2016
P1/2, N=10, Active, not recruiting, Sponsor: Providence Health & Services
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016 Recruiting --> Active, not recruiting | N=37 --> 10
- ||| MEDI6469 / AstraZeneca
Enrollment closed, Combination therapy, Metastases: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (clinicaltrials.gov) - Dec 25, 2015
P1/2, N=58, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | N=37 --> 10 Recruiting --> Active, not recruiting
- ||| MEDI6469 / AstraZeneca
Enrollment change, Combination therapy, Metastases: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=58, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting N=212 --> 58
- cyclophosphamide / Generic mfg.
Trial primary completion date, Metastases: Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer (clinicaltrials.gov) - Sep 29, 2015
P1/2, N=37, Recruiting, Sponsor: Providence Health & Services
N=212 --> 58 Trial primary completion date: Oct 2015 --> Oct 2016
- | MEDI6469 / AstraZeneca
New P1 trial, Combination therapy, IO biomarker, Metastases: Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 24, 2015
P1, N=44, Recruiting, Sponsor: Providence Health & Services
- || MEDI6469 / AstraZeneca
Trial primary completion date, Combination therapy, Metastases: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (clinicaltrials.gov) - Apr 21, 2015
P1/2, N=212, Recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Aug 2016 --> Nov 2016
- MEDI6469 / AstraZeneca
New P1 trial, IO biomarker, Metastases: Anti-OX40 Antibody in Head and Neck Cancer Patients (clinicaltrials.gov) - Oct 24, 2014
P1, N=55, Recruiting, Sponsor: Providence Health & Services
- || MEDI6469 / AstraZeneca
Trial primary completion date, Combination therapy, Metastases: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (clinicaltrials.gov) - Oct 2, 2014
P1/2, N=212, Recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Aug 2016 --> Nov 2016 Trial primary completion date: Aug 2015 --> Jun 2016
- |||| MEDI6469 / AstraZeneca
Enrollment open, Trial primary completion date, Combination therapy, Metastases: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (clinicaltrials.gov) - Aug 25, 2014
P1/2, N=252, Recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Aug 2015 --> Jun 2016 Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> Aug 2015
- ||||| MEDI6469 / AstraZeneca
New P1/2 trial, Combination therapy, Metastases: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (clinicaltrials.gov) - Aug 1, 2014
P1/2, N=252, Not yet recruiting, Sponsor: MedImmune LLC
- MEDI6469 / AstraZeneca
New P1/2 trial, Combination therapy, Metastases: Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (clinicaltrials.gov) - May 23, 2013
P1/2, N=40, Recruiting, Sponsor: Providence Health & Services